| Trial ID: | L6322 |
| Source ID: | NCT00371007
|
| Associated Drug: |
Mk0431, Sitagliptin Phosphate / Duration Of Treatment: 12 Weeks
|
| Title: |
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|DRUG: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks
|
| Outcome Measures: |
Primary: HbA1c, safety and tolerability | Secondary: Plasma glucose
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
126
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2004-06-01
|
| Completion Date: |
2005-04-25
|
| Results First Posted: |
|
| Last Update Posted: |
2017-04-04
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00371007
|
